Data from EMC - Curated by Toby Galbraith - Last updated 24 April 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types.

The use of Cervarix should be in accordance with official recommendations.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone


Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

Visit Prostate Cancer


Related Content

More information

Category Value
Agency product number EMEA/H/C/000721
Orphan designation No
Date First Approved 20-09-2007
Type Medicinal product subject to medical prescription
Marketing authorisation holder GlaxoSmithKline Biologicals S.A.